SCHEMBL3265331

SCHEMBL3265331

C=CC(=O)Nc1ccc(O)cc1C(=O)OC

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 5/20 0.56
CA1 P00915 5/20 0.56
CA2 P00918 5/20 0.56
CA7 P43166 5/20 0.56
CA9 Q16790 5/20 0.56
CA14 Q9ULX7 5/20 0.56
PDK2 Q15119 1/20 0.56
PDK4 Q16654 1/20 0.56
HPGD P15428 2/20 0.46
HTT P42858 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
TGM2 P21980 2/20 0.44
KDM4E B2RXH2 3/20 0.43
MAPT P10636 1/20 0.43
ATM Q13315 1/20 0.43
GAA P10253 3/20 0.42
ALDH1A1 P00352 3/20 0.42
GLA P06280 1/20 0.42
HSD17B10 Q99714 1/20 0.42
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21431006 0.88 TGM2 (0.56) HPGDHTTSMN1; SMN2TGM2KDM4E
SCHEMBL3267660 0.85 PTPRC (0.44) CA12CA1CA2CA7CA9
SCHEMBL4736951 0.85 ABL1 (0.49) HPGDHTTSMN1; SMN2TGM2KDM4E
SCHEMBL4736645 0.81 HPGD (0.68) HPGDHTTSMN1; SMN2KDM4EMAPT
SCHEMBL1025962 0.80 CA12 (0.62) CA12CA1CA2CA7CA9
SCHEMBL1083253 0.78 TGM2 (0.44) HPGDHTTSMN1; SMN2TGM2KDM4E
SCHEMBL13921949 0.78 CA12 (0.56) CA12CA1CA2CA7CA9
SCHEMBL4732816 0.78 KDM4E (0.57) HPGDHTTKDM4EMAPTGAA
SCHEMBL21392831 0.77 KDM4E (0.70) HPGDSMN1; SMN2KDM4EMAPTATM
SCHEMBL23796470 0.76 CA12 (0.62) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110294853-A1 Bis Aromatic Compounds for Use in the Treatment of Inflammation BIOLIPOX AB (SE) 2011-12-01 US disclosed
WO-2010029300-A1 BIS AROMATIC COMPOUNDS FOR USE IN THE TREATMENT OF INFLAMMATION BIOLIPOX AB (SE) 2010-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110294853-A1 Bis Aromatic Compounds for Use in the Treatment of Inflammation LTC4S, LTB4R2, LTB4R CA12 4288/4885CA1 4414/4885CA2 2652/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.